Jessica Scales, PhD, of the Melanoma Research Alliance, reviewed clinical trial access and clinician involvement in the RARE ...

Eingun James Song, MD, explains bone alkaline phosphatase trends and growth considerations in pediatric atopic dermatitis.

The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.

Jessica Scales, PhD, of the Melanoma Research Alliance, discussed the new RARE Registry data report and dermatologists’ role ...

Mark Lebwohl, MD, describes his approach on when to start systemic therapy, access considerations, and dupilumab safety and ...

One clinical trial widened a patient's time in the sun, yet fear of hidden light sources remained. The conversation also ...

Two oral trial drugs changed one patient's daily life, culminating in his first beach visit without protective gear. He and ...

A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...

Trickett and Neita compare adalimumab, secukinumab, and bimekizumab trial data and explain how comorbidities guide biologic ...

An 83-year-old patient's three-decade psoriasis journey, shaped by a comorbid MGUS diagnosis and a hospitalization that ...

Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 REMIND findings for remibrutinib.

Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...